Opinion|Videos|November 4, 2024
Current Practices in B7-H3 Testing
Author(s)Joshua K. Sabari, MD
Joshua K. Sabari, MD, discusses whether individual B7-H3 analysis is available at his institution, noting that, if it is, he obtains IHC for both PD-L1 and B7-H3 expression levels in all patients with SCLC. If B7-H3 testing becomes available, he would consider adding it to the biomarker assay, particularly at the time of diagnosis or recurrence.
Episodes in this series
Video content above is prompted by the following:
- Is individual B7-H3 analysis currently available at your institution ?
If so, do you obtain IHC for both PD-L1 and B7-H3 expression levels in all your patients with SCLC?
If not, when IHC and/or PC does become available for B7-H3 testing, would you consider adding it to your biomarker assay?
o At which stage of disease
